National Institute on Minority Health and Health Disparities (NIMHD)
Watts Healthcare Corporation
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Signed and dated informed consent form and HIPPA (Health Insurance Portability and Accountability Act) authorization.
Stated willingness to comply with all study procedures and availability for the duration of the study.
Male patients 18 years or older
Diagnosed with metastatic prostate cancer
History of confirmed progressive disease with concurrent use of medical castration (e.g. luteinizing hormone-releasing hormone analogue), or surgical castration
Confirmed progressive disease with concurrent use of enzalutamide, apalutamide, darolutamide, and/or abiraterone acetate
Clinical decision to start doc infusion with prednisone treatment
Adequate bone marrow function (absolute neutrophil count (ANC) more than1500 cells/mm³, platelet count more than 100,000 cells/mm³)
Adequate liver function (total bilirubin less than upper limit of normal (ULN), alanine aminotransferase (ALT) less than 1.5 x ULN, aspartate aminotransferase (AST) less than 1.5 x ULN)
Adequate renal function (serum creatinine level within normal limits)
At least a 6-month or greater life expectancy
Willing to stop consuming tea or tea-containing products and quercetin supplements throughout the entire intervention period except for the green tea extract and quercetin provided during study intervention
You may not be if
Prior treatment of chemotherapy and/or radiotherapy for metastatic disease
Any comorbid condition that would preclude the administration of docetaxel/prednisone
Ongoing alcohol abuse
Significant medical or psychiatric conditions that would make the patient a poor protocol candidate
Prior allergic reaction to tea, tea products or quercetin supplements
Allergies to multiple food items or nutritional supplements
